Ismene L Petrakis1,2, Elizabeth Ralevski3,4, Ralitza Gueorguieva5,6, Matthew E Sloan3,4, Lesley Devine5,6, Gihyun Yoon3,4, Albert J Arias7, Mehmet Sofuoglu3,4. 1. Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Avenue, Mail code 116-A, West Haven, CT, 06516, USA. ismene.petrakis@yale.edu. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. ismene.petrakis@yale.edu. 3. Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Avenue, Mail code 116-A, West Haven, CT, 06516, USA. 4. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 5. Department of Biostatistics, School of Public Health, Yale University School of Medicine, New Haven, CT, USA. 6. Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA. 7. Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Abstract
RATIONALE: Alcohol has both acute and chronic effects on neuroimmune signaling, including triggering pro-inflammatory cytokine release by microglia. Minocycline, a second-generation tetracycline antibiotic, inhibits microglial activation and reduces neuroinflammation in preclinical studies. In mice, minocycline also reduces ethanol intake, attenuates ethanol-induced conditioned place preference, and inhibits ethanol-induced microglial activation and pro-inflammatory cytokine release. OBJECTIVE: Here, for the first time, we tested the effects of minocycline on subjective response to ethanol and acute ethanol-induced inflammation in humans. METHODS:Forty-eight heavy drinkers participated in a double-blind, placebo-controlled trial in which they were randomized to receive placebo, 100 mg, or 200 mg of minocycline for 10 days. Each subject then underwent two experimental sessions in which they were given a fixed dose of intravenous ethanol using a "clamp" procedure (100 mg%) or placebo (normal saline) on days 8 and 10 of treatment. RESULTS:Minocycline was well tolerated, but there was no effect of either dose of minocycline on subjective response to ethanol or ethanol-induced craving; minocycline effects on cognitive function seem to interact with age. Minocycline treatment did not alter serum cytokine levels at baseline or during ethanol-exposure, although certain baseline cytokine levels predict sedative response to ethanol. CONCLUSION: These findings indicate that a short-term treatment with minocycline may not alter ethanol-related inflammation or subjective response to ethanol in humans. Further research is needed to identify pharmacological agents with robust effects on ethanol-induced inflammation to determine whether neuroimmune modulation represents a viable treatment strategy for alcohol use disorder.
RCT Entities:
RATIONALE: Alcohol has both acute and chronic effects on neuroimmune signaling, including triggering pro-inflammatory cytokine release by microglia. Minocycline, a second-generation tetracycline antibiotic, inhibits microglial activation and reduces neuroinflammation in preclinical studies. In mice, minocycline also reduces ethanol intake, attenuates ethanol-induced conditioned place preference, and inhibits ethanol-induced microglial activation and pro-inflammatory cytokine release. OBJECTIVE: Here, for the first time, we tested the effects of minocycline on subjective response to ethanol and acute ethanol-induced inflammation in humans. METHODS: Forty-eight heavy drinkers participated in a double-blind, placebo-controlled trial in which they were randomized to receive placebo, 100 mg, or 200 mg of minocycline for 10 days. Each subject then underwent two experimental sessions in which they were given a fixed dose of intravenous ethanol using a "clamp" procedure (100 mg%) or placebo (normal saline) on days 8 and 10 of treatment. RESULTS:Minocycline was well tolerated, but there was no effect of either dose of minocycline on subjective response to ethanol or ethanol-induced craving; minocycline effects on cognitive function seem to interact with age. Minocycline treatment did not alter serum cytokine levels at baseline or during ethanol-exposure, although certain baseline cytokine levels predict sedative response to ethanol. CONCLUSION: These findings indicate that a short-term treatment with minocycline may not alter ethanol-related inflammation or subjective response to ethanol in humans. Further research is needed to identify pharmacological agents with robust effects on ethanol-induced inflammation to determine whether neuroimmune modulation represents a viable treatment strategy for alcohol use disorder.
Authors: Sherry A McKee; Andrea H Weinberger; Julia Shi; Jeanette Tetrault; Sabrina Coppola Journal: Nicotine Tob Res Date: 2012-04-06 Impact factor: 4.244
Authors: Mehmet Sofuoglu; Marc Mooney; Thomas Kosten; Andrew Waters; Kenji Hashimoto Journal: Psychopharmacology (Berl) Date: 2010-09-14 Impact factor: 4.530
Authors: Karin Kerfoot; Brian Pittman; Elizabeth Ralevski; Diana Limoncelli; Julia Koretski; Jenelle Newcomb; Albert J Arias; Ismene L Petrakis Journal: Alcohol Clin Exp Res Date: 2013-07-29 Impact factor: 3.455
Authors: Marappa G Subramanian; Sarah H Heil; Michael L Kruger; Karen L Collins; Philip O Buck; Tina Zawacki; Antonia Abbey; Robert J Sokol; Michael P Diamond Journal: Alcohol Clin Exp Res Date: 2002-10 Impact factor: 3.455
Authors: Michal Bajo; Reesha R Patel; David M Hedges; Florence P Varodayan; Roman Vlkolinsky; Tony D Davis; Michael D Burkart; Yuri A Blednov; Marisa Roberto Journal: Brain Sci Date: 2019-12-07
Authors: Marcella Rietschel; Rainer Spanagel; Stephanie H Witt; Lea Zillich; Eric Poisel; Josef Frank; Jerome C Foo; Marion M Friske; Fabian Streit; Lea Sirignano; Stefanie Heilmann-Heimbach; André Heimbach; Per Hoffmann; Franziska Degenhardt; Anita C Hansson; Georgy Bakalkin; Markus M Nöthen Journal: Transl Psychiatry Date: 2022-05-06 Impact factor: 7.989
Authors: Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray Journal: Brain Behav Immun Date: 2021-07-31 Impact factor: 19.227